Vitamin D in Pain Management.
Study Goal
The researchers aimed to review the potential role of vitamin D (synthesized in sunlight) in managing nociceptive and inflammatory pain, particularly in deficient individuals.
Results Summary
Observational studies linked low vitamin D levels to increased pain and higher opioid use, while interventional studies showed promising pain-reducing effects of supplementation in deficient patients. Vitamin D may reduce pain via anti-inflammatory mechanisms, including inhibition of PGE2, but more rigorous studies are needed for definitive conclusions.
Population
Patients with vitamin D deficiency (25-OHD <30 nmol/L) and those with sufficient levels (25-OHD >50 nmol/L).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
vitamin D supplementation | decrease | cancer pain | patients with insufficient levels of vitamin D when starting intervention | - | shown promising effects | #1 |
vitamin D supplementation | decrease | muscular pain | patients with insufficient levels of vitamin D when starting intervention | - | shown promising effects | #2 |
vitamin D | decrease | inflammation | - | - | anti-inflammatory effects mediated by reduced cytokine and prostaglandin release | #3 |
vitamin D | decrease | Prostaglandin E2 (PGE2) | - | - | inhibition | #4 |
vitamin D supplementation | decrease | pain | patients with deficient levels defined as 25-hydroxyvitamin D (25-OHD) levels <30 nmol/L | - | most likely to benefit | #5 |
vitamin D supplementation | no change | pain | individuals with 25-OHD >50 nmol/L | - | probably have little benefit | #6 |
vitamin D | decrease | pain | patients with vitamin D deficiency | - | may constitute a safe, simple and potentially beneficial way to reduce | #7 |
Vitamin D is a hormone synthesized in the skin in the presence of sunlight. Like other hormones, vitamin D plays a role in a wide range of processes in the body. Here we review the possible role of vitamin D in nociceptive and inflammatory pain. In observational studies, low vitamin D levels have been associated with increased pain and higher opioid doses. Recent interventional studies have shown promising effects of vitamin D supplementation on cancer pain and muscular pain-but only in patients with insufficient levels of vitamin D when starting intervention. Possible mechanisms for vitamin D in pain management are the anti-inflammatory effects mediated by reduced cytokine and prostaglandin release and effects on T-cell responses. The recent finding of vitamin D-mediated inhibition of Prostaglandin E2 (PGE2) is especially interesting and exhibits a credible mechanistic explanation. Having reviewed current literature, we suggest that patients with deficient levels defined as 25-hydroxyvitamin D (25-OHD) levels <30 nmol/L are most likely to benefit from supplementation, while individuals with 25-OHD >50 nmol/L probably have little benefit from supplementation. Our conclusion is that vitamin D may constitute a safe, simple and potentially beneficial way to reduce pain among patients with vitamin D deficiency, but that more randomized and placebo-controlled studies are needed before any firm conclusions can be drawn.